90 results about "Healthy subjects" patented technology

The invention belongs to the technical field of artificial intelligence, and discloses a signal data processing method of an Alzheimer's disease and frontotemporal dementia diagnosis method, which comprises the following steps: selecting an electroencephalogram channel by adopting PSO (Particle Swarm Optimization) and converting computer signal time sequence data into a time-frequency diagram by using wavelet transform, so as to realize accurate diagnosis of Alzheimer's disease patients and healthy subjects. And patients with frontotemporal dementia and healthy subjects as well as patients with Alzheimer's disease and patients with frontotemporal dementia can be accurately and efficiently classified. The PSO is used for selecting a channel combination with good electroencephalogram energy and reducing information interference caused by redundant electroencephalogram channels, a time-frequency graph obtained through wavelet transformation can provide time information and frequency information of electroencephalogram signals at the same time, the model can learn features more effectively, and the classification performance of the model is improved. According to the method disclosed by the invention, the accuracy of classification of the Alzheimer's disease patients and healthy subjects, the frontotemporal dementia patients and healthy subjects, and the Alzheimer's disease patients and the frontotemporal dementia patients is remarkably improved.

A method for identifying biomarkers indicative of neurodegeneration using a covariance neural network (VNN) includes providing a VNN trained on brain anatomical data primarily composed of healthy subjects, making the largest proportion of the population in the data. Brain anatomical data of a subject is provided as input, and, based on the input, the VNN generates a set of biomarkers and a brain health marker indicative of neurodegeneration of the subject.

The invention discloses a PID (Proportion Integration Differentiation) electrical stimulation balance rehabilitation method based on a damage synergistic effect. According to the method, firstly, myoelectricity and IMU joint movement data of a healthy subject on a disturbance platform are collected, non-negative matrix factorization (NMF) is conducted on the myoelectricity data, and the muscle synergistic effect of the healthy subject under a disturbance normal form is solved; myoelectricity and IMU signals of stroke patients in the same disturbance normal form are collected, nonnegative matrix factorization is carried out on the myoelectricity of the patients, and similarity analysis is carried out on the health synergistic effect and the patient synergistic effect to determine the injury synergistic effect. The injury synergistic effect is applied to adjustment of electrical stimulation pulse width parameters and used for conducting electrical stimulation on lower limb muscles, joint angle data are collected in real time, PID electrical stimulation control based on the injury synergistic effect is achieved, and therefore a patient can track a joint angle track of a healthy subject under a disturbance normal form. The patient is assisted to recover the injury synergistic effect under the disturbance normal form, the balance capacity is improved, and a new path is developed for rehabilitation treatment of the stroke patient.

A method of detecting the level of 5-hydroxymethylcytosines (5-hmc) in a DNA molecule of a cell having a 5-hmc prevalence lower than 0.002% of total DNA bases is provided. The method comprising:(a) attaching a 5-hmc labeling agent to the DNA molecule; and(b) subjecting the DNA molecule to an imaging method suitable for detecting the labeling agent, thereby detecting the level of 5-hmc in the DNA molecule. Also provided is a method of diagnosing cancer in a subject in need thereof, the method comprising:(a) providing a DNA sample of a cell of the subject;(b) detecting the level of 5-hmc in the DNA sample as described herein; wherein a significant decrease in the level of 5-hmc in the DNA sample, as compared to a control DNA sample from a healthy subject is indicative that the subject has cancer.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

Disclosed are methods to generate biomarkers that can be used for detection of phenotypes in patients. In an example, a method includes obtaining, from a cohort of subjects, a first plurality of samples from healthy subjects and a second plurality of samples from subjects with a phenotype, and generating sequencing data for the samples. The sequencing data may be used to generate a file having a file format (e.g., a.cpg file), and preliminary segmentation may be performed. Biomarker candidates may be generated by applying a model, and the biomarker candidates scored and / or prioritized to obtain biomarkers for a phenotype. The biomarkers may subsequently be used in a panel to detect the phenotype in a subject.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention relates to a brain anomaly network positioning method and system based on functional connection network mapping in the technical field of neural image data processing. The brain abnormal network positioning method comprises the following steps: calculating a whole brain function network diagram connected with each abnormal site by using resting state function connection data of large-scale health subjects based on a plurality of dispersed abnormal sites reported in previous literatures; then superposing the function network diagrams to obtain a network probability graph; and finally, filtering the probability graph through a threshold value to obtain a final core anomaly network graph. According to the method, the inherent functional connection architecture of the brain is used as a reference system, abnormal sites which seem to be uncorrelated in different researches are successfully traced and unified to a common and stable functional network, and compared with a single brain region marker, the generated network-level biomarker integrates more source evidences, so that the network-level biomarker has the advantages that the network-level biomarker can be widely applied to the field of biomarkers of the brain region. Therefore, the problems of result heterogeneity and inconsistency in brain abnormality discovery are solved.

The present invention relates to esters of formula (I) or pharmaceutically acceptable salts thereof and their use as medicaments, in particular for the treatment of skin diseases or skin cancer. The present invention further relates to the use of esters of formula (I) or pharmaceutically acceptable salts thereof in cosmetic and nutritional compositions for preventing or reducing the signs of aging in healthy subjects.

The invention discloses a primary hypertension risk assessment method based on infrared thermal imaging. The method comprises the following steps: (1) respectively taking two-hand infrared thermograms of a healthy subject, a hypertension patient and a hypertension patient before and after cold stimulation by adopting a medical infrared thermal imager; (2) analyzing hand infrared thermograms before and after cold stimulation of a healthy subject, a hypertensive patient and a hypertensive patient so as to reflect vascular reactivity and blood perfusion states of hands of the healthy subject, the hypertensive patient and the hypertensive patient; and (3) taking hand infrared thermograms of the to-be-tested subject before and after cold stimulation by adopting a medical infrared thermal imager, and obtaining a judgment result according to the vascular reactivity and blood perfusion state of the hand. According to the invention, a medical infrared thermal imager is utilized to shoot infrared thermograms of hands of a subject before and after cold stimulation, so that vascular reactivity and blood perfusion states are visually reflected in a non-contact, real-time and visualized manner, and finally, the purpose of evaluating the risk of primary hypertension is achieved.

The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and / or improving athletic ability.

A method of selecting a treatment for a subject having cancer is disclosed. The method comprises:(a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and(b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of the DNA repair enzyme as compared to the catalytic activity of the DNA repair enzyme in a biological sample of a healthy subject.

The invention disclosed herein concerns screening and early detection of a variety of disease conditions in seemingly healthy subjects, enabling early intervention and treatment.

This invention relates to the field of rehabilitation training technology, and discloses a method for determining amblyopia perception training data and amblyopia perception training visual targets. The method includes: acquiring test data of the target subject, wherein the test data is data obtained from a basic amblyopia perception test of the target subject; determining the initial contrast sensitivity data of the target subject based on the test data; acquiring reference contrast sensitivity data, wherein the reference contrast sensitivity data is obtained from amblyopia perception tests of healthy subjects of the same age as the target subject; determining the target subject's weak data based on the initial contrast sensitivity data and the reference contrast sensitivity data; and determining the target subject's training data based on the weak data. This invention focuses on targeted training in weak areas, reducing ineffective training in normal areas, saving a significant amount of unnecessary training time, and improving the efficiency and targeting of amblyopia perception training.

The present invention provides the use of UTP6 in the preparation of a product for diagnosing polycystic ovary syndrome, relating to the field of biotechnology. Compared with healthy subjects, UTP6 is differentially expressed in patients with polycystic ovary syndrome. The expression of UTP6 is related to polycystic ovary syndrome, and the diagnosis of polycystic ovary syndrome can be achieved by detecting the expression level of UTP6. In addition, compared with healthy subjects, PIAS4 is differentially expressed in patients with polycystic ovary syndrome. The expression of PIAS4 is related to polycystic ovary syndrome, and the combined use of UTP6 and PIAS4 for the diagnosis of polycystic ovary syndrome has higher detection accuracy.

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.

The invention discloses application of FGL1 protein in preparation of a kit for diagnosing vertigo. Clinically, diagnosis of vertigo depends on diagnosis experience of doctors, complaint of patients becomes a main diagnosis basis, the doctors perform preliminary diagnosis according to physical examination, medical history inquiry and the like and then perform clear diagnosis according to etiological examination, diagnosis time is long, and preliminary diagnosis subjectivity is high. It is found that the FGL1 protein can effectively diagnose and distinguish healthy subjects and patients with vertigo, the diagnosis accuracy is high, the FGL1 protein can be used for being developed into a kit for diagnosing vertigo, and compared with an existing diagnosis method, the diagnosis efficiency and objectivity are obviously improved.

The invention belongs to the field of neurological disease diagnosis, and provides a plasma lipid marker for diagnosing Alzheimer's disease and application thereof, and the plasma lipid marker is selected from one or more of PA 16: 016: 0, PE O-18: 022: 4, PE P-16: 022: 4, TG 46: 4-FA18: 2, LPC 22: 4, ChE 22: 4, ChE 22: 0, ChE 20: 2, ChE 18: 0, ChE 16: 1 and ChE 20: 1. According to the present invention, the area under the curve (ROC) of the Alzheimer's disease subject diagnosed by the 11 plasma lipid markers is up to 1, and the Alzheimer's disease patient and the healthy subject can be accurately distinguished; detection can be completed through a venous blood collection method, a traditional cerebrospinal fluid collection method with higher trauma is replaced, and low-trauma and low-cost large-range crowd screening of the Alzheimer's disease is facilitated.

Provided herein are methods of analyzing DNA comprising degrading forms of DNA sequences that are prevalent in healthy subjects; and detecting sequences that are not degraded. Some such methods facilitate detection of aberrant forms of DNA.

This invention provides an apparatus, method, and storage medium for assessing schizophrenic tendency based on near-infrared data. The apparatus includes a processor configured to: acquire near-infrared data of a subject; process the near-infrared data and convert the processed near-infrared data into a test image; input the test image into a classification model to obtain a classification result for the subject, wherein the classification result indicates the subject's tendency to be either healthy or schizophrenic. This invention normalizes near-infrared data based on a preset data set formed by fusing second data sequences from multiple healthy subjects and multiple schizophrenic individuals. This avoids the loss of brain activation information caused by normalization at different scales, resulting in higher accuracy when the classification model classifies the test image converted from the normalized near-infrared data.

The present disclosure relates, in part, to a composition comprising a nucleic acid, wherein the nucleic acid encodes a protein which has a reduced abundance in a GTPase IMAP family 5 (GIMAP5) deficient subject or at least partially inhibits expression of a protein which has an increased abundance in a GIMAP5 deficient subject, as compared to a healthy subject. In certain embodiments, the composition is a nucleic acid-lipid particle. In certain embodiments, the composition is a polymer-based vehicle. In another aspect, the present disclosure relates to a recombinant viral vector comprising a nucleic acid encoding a protein which has a reduced abundance in a GIMAP5 deficient subject as compared to a healthy subject. In yet another aspect, the present disclosure provides a method of treating, ameliorating, and / or preventing liver disease and / or portal hypertension in a subject with administration of one or more compositions and / or vectors of the present disclosure.

Disclosed herein are cytokine constructs that include a delivery vehicle, and at least one cytokine or one decoy receptor. By adjusting the types and density of cytokines on the constructs, they can be tailored for both local and systemic treatment of patients with cancers and other immune-related diseases, such as autoimmune diseases. Additionally, the cytokine constructs can be used ex vivo to expand and activate cells from patients or healthy subjects before re-infusing the activated cells back into patients, which benefits adoptive and stem cell therapies. These constructs display improved half-life and stability of cytokines, enabling reducing doses, and minimizing toxicity from unintended effects of free cytokines. Furthermore, the constructs allow for co-delivery of other therapeutics, such as antibodies, small molecule inhibitors, chemotherapeutics, oligonucleotides, adjuvants, and antigens.

To determine a mild cognitive impairment or its risk highly accurately.SOLUTION: An information processing system has a control unit. The control unit is configured to let level information on D-amino acid in a bio-sample collected respectively from a healthy subject, and a subject who is evaluated that the subject could suffer from at least a mild cognitive impairment on the basis of a prescribed examination, and cohabitant composition information indicative of a cohabitant composition of each subject be an explanatory variable; input level information on the D-amino acid in the bio sample collected from an arbitrary user, and cohabitant composition information indicative of a cohabitant composition of the user into a learned model generated by learning to predict presence or absence of the mild cognitive impairment of each subject, or its risk thereof; and acquire determination information on the presence or absence of the mild cognitive impairment or its risk of the user predicted by the learned model, from the learned model.SELECTED DRAWING: Figure 6

The invention belongs to the field of biological medicine, and particularly relates to a reagent and a kit for detecting lung squamous cell carcinoma and application. According to the kit for detecting lung squamous cell carcinoma, lung squamous cell carcinoma subjects and healthy subjects can be effectively distinguished by detecting the methylation level of the target region of the DLX2-AS1 gene in a sample, a biomarker capable of being used for lung squamous cell carcinoma detection is provided, and the sensitivity and specificity of lung squamous cell carcinoma detection are improved while non-invasive detection is achieved.

Provided herein are computer-implemented methods of detecting cardiovascular disease in a subject. The methods include receiving an electrocardiogram (ECG) image for the subject; applying a machine-learning based algorithm to the ECG image for the subject, the algorithm being trained to distinguish a printed ECG reading of a heart with cardiovascular disease from a printed ECG reading of a healthy heart; comparing outputs of the algorithm to patterns of algorithm outputs for ECG images from healthy subjects and subjects with one or more cardiovascular diseases; and determining if the subject has cardiovascular disease based upon the outputs of the algorithm.

The invention discloses a detection reagent for diagnosis or auxiliary diagnosis of prostate cancer, a kit and application, and belongs to the technical field of molecular biological detection. The detection reagent is used for detecting the methylation level of a target region in a subject sample, and the target region is selected from the full-length or partial region of a nucleotide sequence as shown in SEQ ID NO.1. The methylation level of the target area in the subject sample is detected by using the detection reagent, so that prostatic cancer subjects and healthy subjects can be efficiently and effectively distinguished, and the kit has the advantages of high sensitivity, high specificity and the like while painless, non-invasive, economical, convenient, accurate and efficient screening is realized, so that the kit has a good application prospect. Good application prospects are realized in preparation of prostate cancer auxiliary diagnosis or screening products.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

The invention provides a kit for detecting polysaccharide ligand level and application thereof, and relates to the field of biological detection. The invention finds that the ligand level of polysaccharide compound A in serum of a patient with uterine prolapse is obviously lower than that of a healthy subject for the first time. The reagent for detecting the level of the ligand of the polysaccharide compound A is used for preparing the uterine prolapse screening kit, and effective screening of uterine prolapse can be achieved.